HC Wainwright Has Strong Estimate for TARS FY2025 Earnings

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Research analysts at HC Wainwright lifted their FY2025 earnings estimates for shares of Tarsus Pharmaceuticals in a research report issued on Wednesday, November 5th. HC Wainwright analyst M. Caufield now anticipates that the company will earn ($1.34) per share for the year, up from their previous estimate of ($1.57). HC Wainwright has a “Buy” rating and a $88.00 price objective on the stock. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. HC Wainwright also issued estimates for Tarsus Pharmaceuticals’ Q4 2025 earnings at $0.04 EPS, Q1 2026 earnings at $0.05 EPS, Q2 2026 earnings at $0.09 EPS, Q4 2026 earnings at $0.26 EPS and FY2026 earnings at $0.59 EPS.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.05. Tarsus Pharmaceuticals had a negative net margin of 22.17% and a negative return on equity of 26.29%. The firm had revenue of $118.70 million during the quarter, compared to analyst estimates of $114.22 million.

A number of other brokerages have also weighed in on TARS. Guggenheim boosted their target price on shares of Tarsus Pharmaceuticals from $84.00 to $87.00 and gave the company a “buy” rating in a research note on Wednesday. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $51.00 price objective on shares of Tarsus Pharmaceuticals in a report on Thursday. Zacks Research raised Tarsus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Friday, September 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Wednesday, October 8th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $69.83.

Tarsus Pharmaceuticals Stock Down 0.2%

Shares of Tarsus Pharmaceuticals stock opened at $68.09 on Friday. Tarsus Pharmaceuticals has a twelve month low of $38.51 and a twelve month high of $76.81. The company has a quick ratio of 5.21, a current ratio of 4.29 and a debt-to-equity ratio of 0.22. The company’s 50 day moving average is $62.57 and its 200 day moving average is $51.09. The company has a market cap of $2.87 billion, a price-to-earnings ratio of -33.71 and a beta of 0.82.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 6,000 shares of the business’s stock in a transaction dated Wednesday, September 24th. The stock was sold at an average price of $55.37, for a total transaction of $332,220.00. Following the completion of the sale, the chief executive officer owned 812,106 shares of the company’s stock, valued at approximately $44,966,309.22. The trade was a 0.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director William J. Phd Link sold 27,116 shares of the company’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $57.00, for a total value of $1,545,612.00. Following the completion of the sale, the director owned 143,332 shares of the company’s stock, valued at approximately $8,169,924. The trade was a 15.91% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 39,116 shares of company stock worth $2,177,832 over the last quarter. 8.97% of the stock is owned by company insiders.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Amalgamated Bank raised its stake in Tarsus Pharmaceuticals by 30.1% during the 1st quarter. Amalgamated Bank now owns 1,274 shares of the company’s stock worth $65,000 after acquiring an additional 295 shares during the period. Arizona State Retirement System increased its stake in shares of Tarsus Pharmaceuticals by 6.1% in the first quarter. Arizona State Retirement System now owns 8,182 shares of the company’s stock worth $420,000 after purchasing an additional 470 shares in the last quarter. Victory Capital Management Inc. raised its position in shares of Tarsus Pharmaceuticals by 999.5% during the 1st quarter. Victory Capital Management Inc. now owns 44,320 shares of the company’s stock valued at $2,277,000 after purchasing an additional 40,289 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Tarsus Pharmaceuticals during the 1st quarter valued at $1,818,000. Finally, Thoroughbred Financial Services LLC boosted its holdings in Tarsus Pharmaceuticals by 16.1% in the 1st quarter. Thoroughbred Financial Services LLC now owns 5,510 shares of the company’s stock worth $283,000 after buying an additional 765 shares during the period. 90.01% of the stock is owned by hedge funds and other institutional investors.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.